Meet ApplyKite Twin, the application assistant that learns with you

Meet your Twin, it learns with you

Your Twin learns with you

Launch week codes:30% off annual Pro20% off monthly Pro

Ends in00h00m00s

Nikhil Khushalani

Assistant Center Director for Clinical Research Review and Partnerships; Senior Member and Vice-Chair, Department of Cutaneous Oncology

H Lee Moffitt Cancer Center and Research Institute

United States

Research Interests

Explore related searches

Professors in United States Professors in Immunology Immunology professors in United States

Articles (13)

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Collaborators (11)

Marina Bastawrous Jacob

University of South Florida

UNITED STATES

View details

Elad Sharon

Associate Professor

Harvard University

UNITED STATES

View details

John Kirkwood

Distinguished Service Professor of Medicine

University of Pittsburgh

UNITED STATES

View details

Eissa Jafari

Assistant Professor

jazan university

SAUDI ARABIA

View details

Hanfei Qi

Johns Hopkins University

UNITED STATES

View details

Ahmad Tarhini

Senior Member, Professor

H Lee Moffitt Cancer Center and Research Institute

UNITED STATES

View details

Andrew Brohl

Associate Member

H Lee Moffitt Cancer Center and Research Institute

UNITED STATES

View details

Paul Nghiem

Professor

University of Washington

UNITED STATES

View details

Robert Ferris

UPMC Endowed Professor

University of Pittsburgh School of Medicine

UNITED STATES

View details

Neil H. Segal

Weill Cornell Medicine

UNITED STATES

View details

James Gulley

Co-Director

National Cancer Institute

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Nikhil Khushalani

Research Interests

Explore related searches

Articles (13)

Addressing Biases in Analysis of Time of Infusion: NCI/SWOG Trial S1404 Among Participants With High-Risk Resectable Melanoma Who Received Adjuvant Anti–PD-1 Therapy

Survival Assessment by Central Review vs. Local Investigator in Metastatic Melanoma: A Systematic Review and Meta-Analysis

Neoadjuvant Intralesional Daromun in Resectable Melanoma: Interpreting the PIVOTAL Trial

Local Recurrence After Excision of Merkel Cell Carcinoma: What Do We Actually Know, and What Should We Do Next?

Evolving Standards for Resected High-Risk CSCC: Integrating Insights from C-POST and KEYNOTE-630

Phase II Trial of Pembrolizumab in Combination With Bevacizumab for Untreated Melanoma Brain Metastases

Final results of urelumab, an anti-CD137 agonist monoclonal antibody, in combination with cetuximab or nivolumab in patients with advanced solid tumors

Real-World Outcomes with Immuno-Oncology Therapies in Advanced Melanoma: Final Results of the OPTIMIzE Registry Study

Nivolumab + Tacrolimus + Prednisone ± Ipilimumab for Kidney Transplant Recipients With Advanced Cutaneous Cancers

First-in-Human Stage III/IV Melanoma Clinical Trial of Immune Priming Agent IFx-Hu2.0

Neoadjuvant Intratumoral Plasmid IL-12 Electro-Gene-Transfer and Nivolumab in Patients with Operable, Locoregionally Advanced Melanoma

Durability of response to immune checkpoint blockade following treatment discontinuation and efficacy of rechallenge in advanced Merkel cell carcinoma

Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with targeted therapies

Collaborators (11)

Marina Bastawrous Jacob

Elad Sharon

John Kirkwood

Eissa Jafari

Hanfei Qi

Ahmad Tarhini

Andrew Brohl

Paul Nghiem

Robert Ferris

Neil H. Segal

James Gulley

Make your next move.